title: Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
abstract: OBJECTIVE
  To document the therapeutic efficacy and safety of Human Normal Immunoglobulin 10% Liquid (KIOVIG(®)/GAMMAGARD LIQUID(®) [IVIG 10%]) under clinical routine conditions.
  
  
  METHODS
  Subjects received IVIG 10% according to the prescribing information and were followed for 6 ± 1 weeks to 12 ± 2 months depending on indication. Efficacy, adverse events, infusion rates and duration and dose were recorded.
  
  
  RESULTS
  Overall efficacy of IVIG 10% was rated as good or very good by the investigator in 81.8% of subjects; overall tolerability was good or very good in 87.5%. One serious adverse drug reaction (ADR) occurred (urticaria); no severe ADRs occurred.
  
  
  CONCLUSIONS
  In this observational study, the efficacy and safety of IVIG 10% in routine clinical practice was similar to that previously reported in clinical studies.
authors: Faculty Hospital Ostrava, 17 Listopadu 1790, 708 52 Ostava-Poruba, Czech Republic.
authors: Bohumír
authors: B
authors: Blažek
authors: John Radcliffe 2 Hospital Academic Centre L4, Oxford, OX3 9DU, UK.
authors: Siraj A
authors: SA
authors: Misbah
authors: Hospital Universitari Vall D'Hebron, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
authors: Pere
authors: P
authors: Soler-Palacin
authors: Baxter BioScience, Donau-City Strasse 7, 1220 Vienna, Austria.
authors: Barbara
authors: B
authors: McCoy
authors: Baxter BioScience, Donau-City Strasse 7, 1220 Vienna, Austria.
authors: Heinz
authors: H
authors: Leibl
authors: Baxter BioScience, Donau-City Strasse 7, 1220 Vienna, Austria.
authors: Werner
authors: W
authors: Engl
authors: Baxter BioScience, Donau-City Strasse 7, 1220 Vienna, Austria.
authors: Victoria
authors: V
authors: Empson
authors: Baxter Healthcare Corporation, 1 Baxter Way, Westlake Village, CA 3811, USA.
authors: David
authors: D
authors: Gelmont
authors: Baxter Healthcare SA, Zurich, Switzerland.
authors: Nikolai
authors: N
authors: Nikolov
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000009:adverse effects; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy
chemical_list: D016756:Immunoglobulins, Intravenous
keywords: GAMMAGARD LIQUID; KIOVIG; autoimmune disease; immunodeficiency; intravenous immunoglobulin